Kura Oncology (KURA)
(Delayed Data from NSDQ)
$21.06 USD
+0.55 (2.68%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $21.09 +0.03 (0.14%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Cash flow Statements
Fiscal Year End for Kura Oncology, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -152.63 | -135.84 | -130.47 | -89.63 | -63.14 |
Depreciation/Amortization & Depletion | -8.57 | 2.37 | 4.95 | 0.60 | -1.10 |
Net Change from Assets/Liabilities | 7.82 | -2.98 | -3.22 | 6.38 | 0.07 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 28.56 | 26.39 | 24.19 | 12.81 | 9.41 |
Net Cash From Operating Activities | -124.82 | -110.06 | -104.55 | -69.83 | -54.76 |
Property & Equipment | -0.17 | -0.63 | -1.15 | -2.17 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 15.72 | 33.25 | -125.69 | -97.77 | -46.33 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 15.56 | 32.63 | -126.84 | -99.94 | -46.33 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 94.78 | 29.14 | 4.43 | 469.58 | 111.10 |
Issuance (Repayment) of Debt | 0.00 | 10.00 | -7.25 | -0.25 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | -0.58 | -0.61 | 0.00 | 0.00 |
Net Cash from Financing Activities | 94.78 | 38.57 | -3.44 | 469.33 | 111.10 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -14.48 | -38.87 | -234.82 | 299.57 | 10.02 |
Cash at Beginning of Period | 51.80 | 90.88 | 325.70 | 26.14 | 16.12 |
Cash at End of Period | 37.32 | 52.01 | 90.88 | 325.70 | 26.14 |
Diluted Net EPS | -2.08 | -2.03 | -1.97 | -1.69 | -1.51 |
Fiscal Year End for Kura Oncology, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -100.36 | -49.53 | -152.63 | -109.85 | -71.24 |
Depreciation/Amortization & Depletion | -6.38 | -3.04 | -8.57 | -6.05 | -3.38 |
Net Change from Assets/Liabilities | -1.82 | -4.92 | 7.82 | 4.11 | -0.93 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 17.19 | 8.63 | 28.56 | 21.27 | 14.06 |
Net Cash From Operating Activities | -91.37 | -48.84 | -124.82 | -90.52 | -61.49 |
Property & Equipment | -0.10 | -0.08 | -0.17 | -0.15 | -0.13 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -52.07 | -95.25 | 15.72 | -26.49 | -35.07 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -52.17 | -95.34 | 15.56 | -26.64 | -35.20 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 151.41 | 148.37 | 94.78 | 94.09 | 94.01 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 151.41 | 148.37 | 94.78 | 94.09 | 94.01 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 7.87 | 4.19 | -14.48 | -23.06 | -2.68 |
Cash at Beginning of Period | 37.32 | 37.32 | 51.80 | 51.80 | 52.01 |
Cash at End of Period | 45.18 | 41.51 | 37.32 | 28.74 | 49.33 |
Diluted Net EPS | -0.59 | -0.59 | -0.55 | -0.50 | -0.53 |